Twelve Years Stable on Desmopressin — and Quietly Trending Toward Low Sodium
A single patient, twelve years into permanent central DI after childhood cancer treatment, on a stable desmopressin dose with a sodium that has crept downward over the past two years. The disagreement is whether tighter dosing or a planned weekly gap in coverage is the safer long-term strategy.
M.V., a 34-year-old woman, works as a set designer for a regional theater company, a job with genuinely unpredictable hours that she has built her entire desmopressin routine around for over a decade, timing her twice-daily intranasal doses to tech-week schedules that shift by weeks at a time. Her central DI dates to childhood, a consequence of the same cranial radiation that treated a pediatric brain tumor she has otherwise been cured of for twenty-six years; she has been on a stable intranasal desmopressin regimen, 10 mcg twice daily, for the past twelve years without a dose change, and describes her polyuria and thirst as fully controlled, with no breakthrough symptoms she can recall in years. What brought this visit forward from her usual annual check is a lab trend her primary care physician flagged: serum sodium 141 mEq/L three years ago, 138 two years ago, 135 last year, and 132 mEq/L today — a slow, consistent downward drift over a dose that has not changed at all in that same window.
The mechanism behind that drift is a genuine, underappreciated hazard of long-term fixed-dose desmopressin rather than a sign her DI itself is worsening: continuous V2-receptor agonism at a dose that was well-matched to her needs twelve years ago can, over years, produce a slow dilutional hyponatremia in patients who continue drinking to thirst without ever experiencing the breakthrough polyuria that would otherwise signal free-water excess and prompt them to hold a dose. Because desmopressin has no built-in escape — unlike her own native vasopressin, which shuts off physiologically once serum osmolality falls, exogenous desmopressin keeps working regardless of how dilute her plasma becomes — years of perfectly "controlled" symptoms can mask a slowly accumulating free-water surplus that shows up first, and often only, in the sodium trend rather than in anything she'd notice day to day. Her cardiac and renal workup today, both normal, closes off the other plausible explanations for a three-year downward drift this steady, leaving the desmopressin mechanism itself as the most likely driver rather than one possibility among several still needing to be ruled out.
Twelve years of the same dose is its own kind of warning sign
I'd move her toward a deliberate once-weekly dose-skip, not tighter scheduled dosing. Her sodium trend is the textbook pattern of slow desmopressin-driven dilutional hyponatremia — perfectly controlled symptoms with a quietly falling sodium, because fixed dosing has no physiologic shutoff the way her own vasopressin would. A planned gap, letting her go through one dose-free interval each week, restores exactly the escape valve continuous dosing removed.
I'd want the skip built around a genuine plan rather than a general instruction to "miss a dose sometimes." Twelve years of a routine timed to unpredictable tech-week schedules is exactly the kind of long-standing habit that erodes under a vague instruction — she needs a specific day and a clear expectation of what she'll feel (breakthrough thirst and urination for several hours) so the planned gap doesn't get quietly skipped or, worse, doubled up on the following dose out of discomfort.
There's also a real risk in the other direction if this isn't explicit: without a defined day, she could end up inconsistently skipping doses around unpredictable work schedules, landing her with irregular breakthrough polyuria that's harder to distinguish from an actual dosing error than a deliberate, planned one would be.
Fair — I'd fix the skip to the same day every week, ideally a day she already has more schedule flexibility, rather than leaving it to float. Recheck sodium at 6 weeks to confirm the trend has actually reversed rather than assuming a mechanistically sound plan is automatically working, and set a lower dose as the fallback if a fixed weekly skip alone doesn't bring her sodium back up.
Agreed: add a fixed, once-weekly desmopressin skip on a day chosen for her greater schedule flexibility, with explicit anticipatory guidance about the several hours of breakthrough thirst and polyuria she should expect that day — framed as the plan working, not a symptom of a problem. Sodium rechecked at 6 weeks to confirm reversal, with a lower daily dose as the named fallback if the skip alone doesn't work.
Both physicians agreed on the mechanism and the general approach quickly; the pharmacologist's contribution was insisting the skip be a fixed, anticipated day rather than a loose instruction, given how erosion-prone a vague change is against a twelve-year routine.